Skip to main content
Erschienen in: Drug Safety 6/2013

01.06.2013 | Short Communication

The Effects of Antitussive Treatment of ACE Inhibitor-Induced Cough on Therapy Compliance: A Prescription Sequence Symmetry Analysis

verfasst von: Stefan Vegter, Pieter de Boer, Klaas Willem van Dijk, Sipke Visser, Lolkje T. W. de Jong-van den Berg

Erschienen in: Drug Safety | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

A common adverse effect of angiotensin-converting enzyme inhibitors (ACEI) is a persistent dry cough. Physicians and pharmacists who fail to recognise dry cough to be ACEI related may prescribe antitussives, instead of recommended ACEI substitution.

Objective

The aim of this study was to determine the influence of antitussive treatment of ACEI-induced cough on ACEI therapy compliance.

Methods

Prescription data from community pharmacies between 2000 and 2012 were retrieved from the IADB.nl database (InterAction Database) in The Netherlands. A prescription sequence symmetry analysis was used to determine whether antitussive agents were prescribed more often following ACEI initiation (cases) than the other way around (controls). ACEI therapy compliance was assessed using the proportion of days covered (PDC) method; patients with a PDC of at least 80 % were considered compliant. Compliance was compared between patients receiving antitussives for ACEI-induced cough and patients receiving antitussives for other reasons and patients who did not receive antitussives.

Results

A total of 1,898 starters of ACEI and antitussives within a half-year time span were included. A significant excess of patients received antitussives after ACEI initiation compared with before ACEI initiation (1,269 cases vs. 629 controls), yielding a sequence ratio of 2.0 (95 % CI 1.8–2.2). The estimated proportion of patients with ACEI-induced cough receiving antitussives decreased over time: from 20.4 % in 2000–2004 to 8.0 % in 2008–2012. ACEI therapy compliance in patients receiving antitussives due to ACEI initiation was 52.4 %, significantly lower than compliance in control patients receiving antitussives for cough unrelated to ACEI (75.5 %, P < 0.001) and control patients who did not receive antitussives (75.2 %, P < 0.001).

Conclusions

Many patients receive antitussives after ACEI initiation. This suggests that ACEI-induced cough is often either not recognized as being ACEI related or is symptomatically treated. Such prescription behaviour may decrease ACEI therapy compliance.
Literatur
1.
Zurück zum Zitat Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J. 2009;30(11):1385–94.PubMedCrossRef Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J. 2009;30(11):1385–94.PubMedCrossRef
2.
Zurück zum Zitat Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941–51.PubMedCrossRef Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941–51.PubMedCrossRef
3.
Zurück zum Zitat Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359–64.PubMedCrossRef Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359–64.PubMedCrossRef
4.
Zurück zum Zitat Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf. 1996;15(1):72–8.PubMedCrossRef Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf. 1996;15(1):72–8.PubMedCrossRef
5.
Zurück zum Zitat Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234–42.PubMedCrossRef Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234–42.PubMedCrossRef
7.
Zurück zum Zitat Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Female preponderance for lisinopril-induced cough in hypertension. Am J Hypertens. 1994;7(11):1012–5.PubMed Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Female preponderance for lisinopril-induced cough in hypertension. Am J Hypertens. 1994;7(11):1012–5.PubMed
8.
Zurück zum Zitat Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10(4):499–509. Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10(4):499–509.
9.
10.
11.
Zurück zum Zitat Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):169S–73S.PubMedCrossRef Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):169S–73S.PubMedCrossRef
12.
Zurück zum Zitat Lombardi C, Crivellaro M, Dama A, Senna G, Gargioni S, Passalacqua G. Are physicians aware of the side effects of angiotensin-converting enzyme inhibitors?: a questionnaire survey in different medical categories. Chest. 2005;128(2):976–9.PubMedCrossRef Lombardi C, Crivellaro M, Dama A, Senna G, Gargioni S, Passalacqua G. Are physicians aware of the side effects of angiotensin-converting enzyme inhibitors?: a questionnaire survey in different medical categories. Chest. 2005;128(2):976–9.PubMedCrossRef
13.
Zurück zum Zitat Vegter S. de Jong-van den Berg LT. Misdiagnosis and mistreatment of a common side-effect–angiotensin-converting enzyme inhibitor-induced cough. Br J Clin Pharmacol. 2010;69(2):200–3.PubMedCrossRef Vegter S. de Jong-van den Berg LT. Misdiagnosis and mistreatment of a common side-effect–angiotensin-converting enzyme inhibitor-induced cough. Br J Clin Pharmacol. 2010;69(2):200–3.PubMedCrossRef
14.
Zurück zum Zitat Olsen CG. Delay of diagnosis and empiric treatment of angiotensin-converting enzyme inhibitor-induced cough in office practice. Arch Fam Med. 1995;4(6):525–8.PubMedCrossRef Olsen CG. Delay of diagnosis and empiric treatment of angiotensin-converting enzyme inhibitor-induced cough in office practice. Arch Fam Med. 1995;4(6):525–8.PubMedCrossRef
15.
Zurück zum Zitat Kalisch LM, Caughey GE, Roughead EE. The prescribing cascade. Aust Prescr. 2011;34(6):162–6. Kalisch LM, Caughey GE, Roughead EE. The prescribing cascade. Aust Prescr. 2011;34(6):162–6.
16.
Zurück zum Zitat Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096–9.PubMedCrossRef Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096–9.PubMedCrossRef
17.
Zurück zum Zitat Wallenius SH, Vainio KK, Korhonen MJ, Hartzema AG, Enlund HK. Self-initiated modification of hypertension treatment in response to perceived problems. Ann Pharmacother. 1995;29(12):1213–17. Wallenius SH, Vainio KK, Korhonen MJ, Hartzema AG, Enlund HK. Self-initiated modification of hypertension treatment in response to perceived problems. Ann Pharmacother. 1995;29(12):1213–17.
18.
Zurück zum Zitat Schirm E, Monster TB, de Vries R, van den Berg PB, de Jong-van den Berg LT, Tobi H. How to estimate the population that is covered by community pharmacies? An evaluation of two methods using drug utilisation information. Pharmacoepidemiol Drug Saf. 2004;13(3):173–9. Schirm E, Monster TB, de Vries R, van den Berg PB, de Jong-van den Berg LT, Tobi H. How to estimate the population that is covered by community pharmacies? An evaluation of two methods using drug utilisation information. Pharmacoepidemiol Drug Saf. 2004;13(3):173–9.
19.
Zurück zum Zitat Tobi H, van den Berg PB, de Jong-van den Berg LT. The interaction database: synergy of science and practice in pharmacy. In: Brause RW, Hanisch E, editors. Medical data analysis. Berlin: Springer; 2000. p. 206–11. Tobi H, van den Berg PB, de Jong-van den Berg LT. The interaction database: synergy of science and practice in pharmacy. In: Brause RW, Hanisch E, editors. Medical data analysis. Berlin: Springer; 2000. p. 206–11.
20.
Zurück zum Zitat Leufkens HGM, Urquhart J. Automated pharmacy record linkage in the Netherlands. In: Strom BL, editor. Pharmacoepidemiology. Chichester: Wiley; 2008. p. 347–60. Leufkens HGM, Urquhart J. Automated pharmacy record linkage in the Netherlands. In: Strom BL, editor. Pharmacoepidemiology. Chichester: Wiley; 2008. p. 347–60.
21.
Zurück zum Zitat Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7(5):478–84.PubMedCrossRef Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7(5):478–84.PubMedCrossRef
22.
Zurück zum Zitat Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7.
23.
Zurück zum Zitat Vegter S, Nguyen NH, Visser ST, de Jong-van den Berg LT, Postma MJ, Boersma C. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care. 2011;17(9):609–16. Vegter S, Nguyen NH, Visser ST, de Jong-van den Berg LT, Postma MJ, Boersma C. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care. 2011;17(9):609–16.
24.
Zurück zum Zitat Amin AP, Mukhopadhyay E, Nathan S, Napan S, Kelly RF. Association of medical noncompliance and long-term adverse outcomes, after myocardial infarction in a minority and uninsured population. Transl Res. 2009;154(2):78–89. Amin AP, Mukhopadhyay E, Nathan S, Napan S, Kelly RF. Association of medical noncompliance and long-term adverse outcomes, after myocardial infarction in a minority and uninsured population. Transl Res. 2009;154(2):78–89.
25.
Zurück zum Zitat Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772–9. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772–9.
26.
Zurück zum Zitat Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12(5):639–45.PubMedCrossRef Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12(5):639–45.PubMedCrossRef
27.
Zurück zum Zitat Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303–10. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303–10.
28.
Zurück zum Zitat Böhm M, Baumhäkel M, Mahfoud F, Werner C. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors. Cardiology. 2010;117(3):163–73. Böhm M, Baumhäkel M, Mahfoud F, Werner C. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors. Cardiology. 2010;117(3):163–73.
Metadaten
Titel
The Effects of Antitussive Treatment of ACE Inhibitor-Induced Cough on Therapy Compliance: A Prescription Sequence Symmetry Analysis
verfasst von
Stefan Vegter
Pieter de Boer
Klaas Willem van Dijk
Sipke Visser
Lolkje T. W. de Jong-van den Berg
Publikationsdatum
01.06.2013
Verlag
Springer International Publishing AG
Erschienen in
Drug Safety / Ausgabe 6/2013
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-013-0024-z

Weitere Artikel der Ausgabe 6/2013

Drug Safety 6/2013 Zur Ausgabe